Disitamab vedotin (RC48) is a HER2‐targeted antibody‐drug conjugate consisting of a HER2‐specific antibody, monomethyl auristatin E (MMAE), and a cleavable valine‐citrulline linker, which can selectively bind to HER2‐expressing tumor cells, internalize, and release MMAE intracellularly to exert cytotoxic effects including bystander killing of adjacent heterogeneous tumor cells. The gene discussed is ERBB2; the disease is neoplasm.